Enhancing ARIC Infastructure to Yield a New Cancer Epidemiology Cohort

增强 ARIC 基础设施以产生新的癌症流行病学队列

• 批准号: 9188212
• 负责人: ELIZABETH A. PLATZ
• 金额: $ 21.88万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-15 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9188212
• 关键词: Address; African American; Atherosclerosis; Biological Markers; Blood; Blood specimen; Clinical; Communities; Consent; DNA Sequence; Data; Diabetes Mellitus; Diagnosis; Epidemiologic Studies; Food; Frequencies; Genetic study; Handedness; Health; Histology; Hospitals; Instruction; Interview; Life Style; Link; Location; Malignant Neoplasms; Medical; Medical Records; Molecular Genetics; Natural History; Organ; Participant; Pathology; Pharmaceutical Preparations; Protocols documentation; Questionnaires; Records; Recruitment Activity; Recurrence; Research; Research Infrastructure; Resources; Retreatment; Risk; Schedule; Site; Specimen; Staging; Telephone; Time; Tissues; Update; Urine; Variant; Washington; Woman; adjudicate; aged; anticancer research; cancer diagnosis; cancer epidemiology; cancer recurrence; cohort; cost; fasting glucose; follow-up; genome wide association study; neoplasm registry; novel; operation; receptor; response; risk variant; temporal measurement; working group

We propose to enhance the infrastructure of ARIC, the Atherosclerosis Risk in Communities, cohort to yield a new Cancer Epidemiology Cohort that brings novel features to cancer epidemiology research. In 1987, 15,792 participants aged 45-64 years were recruited from Forsyth Co., NC; Jackson, MS; IVIinneapolis, MN; and Washington Co., MD. 55% are women and 27% are African-American. Participants underwent 4 clinical exams; a 5th is scheduled for 2011. Blood and urine specimens have been banked, medications recorded, and a food frequency questionnaire completed. Participants were interviewed by phone annually and now semi-annually to obtain updated health information. The response at year 21 is 91%. Because ARIC has never been viewed as a Cancer Epidemiology Cohort and infrastructure and cost constraints, only cancer diagnosis has been systematically recorded. By 2006, 3,145 participants were diagnosed with an incident first primary and 376 with a 2nd / 3rd primary. Information, such as stage, grade, histology, location in organ, laterality, receptor status, treatment, recurrence, and re-treatment, needed to address contemporary questions is not currently available. Tissue needed for molecular/genetic studies has not been collected. Thus, we propose: 1) Starting 2012, to prospectively identify cases from semi-annual phone interviews and collect medical/pathology records pertaining to cancer diagnosis, treatment, recurrence, and retreatment and tissue blocks. 2) To retrospectively collect information characterizing cancer diagnoses and recurrences before 2012 from cancer registries in the 4 ARIC states (consent already obtained) and medical records, and collect tissue blocks. By 2016, we expect 4,900 fully annotated incident cases. We established a Cancer Working Group to develop protocols for adjudicating cancer endpoints and prioritize research using the resource. With enhanced infrastructure, we expect that research questions such as these are addressable uniquely in ARIC: 1) What is the association between timing ofthe natural history of diabetes using 4 fasting glucose and 2 HbAlc measurements and timing of cancer diagnosis? 2) Using GWAS and sequencing data, is there a set of risk variants shared by major cancers or are variants specific to each site? RELEVANCE (See instructions): Given the wealth of repeated anthropometric, lifestyle, medical data, blood samples and biomarkers; GWAS on all participants; planned DNA sequencing; approved CMS linkage; 21-year follow-up; African-American representation; established hospital links; and existing operations protocols, with enhanced infrastructure, ARIC will be a mature Cancer Epidemiology Cohort that brings novel features to cancer research.

我们建议加强ARIC的基础设施，社区动脉粥样硬化风险，队列产量 一个新的癌症流行病学队列，为癌症流行病学研究带来了新的特点。一九八七年， 从福赛斯公司招募了15，792名45-64岁的参与者，北卡罗来纳州;杰克逊，密西西比州; 和华盛顿公司，马里兰州55%是女性，27%是非洲裔美国人。参与者接受了4次临床试验 第五次考试定于2011年举行。血液和尿液样本已经储存，药物记录， 并完成食物频率问卷。参与者每年通过电话进行采访，现在 每半年一次，以获取最新的健康信息。第21年的回答率为91%。因为ARIC有 从来没有被视为癌症流行病学队列和基础设施和成本的限制，只有癌症 系统地记录了诊断结果。到2006年，有3,145名参与者被诊断出患有一种疾病， 第一小学和376个第二/第三小学。信息，如分期、分级、组织学、器官中的位置， 解决当代问题所需的偏侧性、受体状态、治疗、复发和再治疗 问题目前不可用。尚未收集分子/遗传研究所需的组织。 因此，我们建议：1）从2012年开始，从半年一次的电话访谈中前瞻性地确定病例， 收集与癌症诊断、治疗、复发和再治疗有关的医疗/病理学记录，以及 组织块2)回顾性收集表征癌症诊断和复发的信息 2012年之前，来自4个ARIC州的癌症登记处（已获得同意）和医疗记录，以及 收集组织块。到2016年，我们预计将有4,900个完全注释的事件案例。我们建立了一个癌症 制定癌症终点判定协议并优先考虑使用 resource.随着基础设施的增强，我们预计这些研究问题是可以解决的 在ARIC中独特的是：1）使用4禁食的糖尿病自然史的时间之间的关系是什么？ 血糖和2 HbAlc测量和癌症诊断的时间？2)使用GWAS和测序数据， 是否存在一组主要癌症共有的风险变体，或者每个部位都有特定的变体？ 相关性（参见说明）： 鉴于大量重复的人体测量、生活方式、医疗数据、血液样本和生物标志物; 所有参与者;计划的DNA测序;批准的CMS联系; 21年随访;非洲裔美国人 代表;已建立的医院联系;现有的业务协议，加强基础设施， ARIC将成为一个成熟的癌症流行病学队列，为癌症研究带来新的特点。